Scholarlink

Background <p>In 2022, a tick control product, against <i>Rhipicephalus microplus</i>, containing fluralaner as the active ingredient was initially launched in the Brazilian market, followed by other markets across Latin America. Once a new molecule is introduced for the control of a parasitic organism, it becomes essential to develop methods for assessing the susceptibility of target parasitic populations. In this context, discriminating dose (DD) tests represent a valuable tool.</p> Methods <p>This study evaluated the susceptibility profile of 200 <i>R. microplus</i> populations originating from 21 federal units (20 states and a federal district) across all five regions of Brazil, using a larval immersion test (LIT) with two discriminating doses (DD) of 1.55 and 3.16&#xa0;µg/mL. Populations showing mortality rates above 95% were classified as susceptible. A field trial was also conducted with one population (São José do Rio Pardo [SJRP]), which had a known history of exposure to fluralaner, to compare laboratory and field test outcomes.</p> Results <p>The DD at a concentration of 1.55&#xa0;µg/mL resulted in 100% mortality in 160 populations (80%), whereas the DD at a concentration of 3.16&#xa0;µg/mL showed more consistent results, with 100% mortality in 182 populations (91%). In the field trial population, SJRP, fluralaner achieved 100% therapeutic efficacy (days +7 to +21) and persistent efficacy (days +28 to +42).</p> Conclusions <p>LIT using DDs can provide indicative data on the susceptibility of <i>R. microplus</i> to fluralaner. The discriminating dose at a concentration of 3.16&#xa0;µg/mL was shown to be the most appropriate for monitoring the susceptibility of <i>R. microplus</i> populations to fluralaner. Laboratory and field data support the classification of the SJRP population as susceptible, demonstrating consistency between the two sets of results. These results can serve as a basis for continuous spatial and temporal monitoring of the susceptibility of <i>R. microplus</i> populations to fluralaner. Continued research, integrating laboratory and field results, is essential to increase the reliability of laboratory-based testing.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Assessing the susceptibility of 200 Rhipicephalus microplus populations to fluralaner using larval immersion test: A nationwide analysis from Brazil

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月16日

查看全文
  • Haile Dean Figueiredo Chagas,
  • Arthur Matos de Santana,
  • Gabriel Webert Gomes,
  • Ana Carolinne Lopes Ascenção,
  • Emanuel Magalhães Souza,
  • Laura Cristina Ferreira Faria,
  • Mayara Macedo Barrozo,
  • Ana Lucia Coutinho Teixeira,
  • Daniel de Castro Rodrigues,
  • Fernando de Almeida Borges,
  • Lívio Martins Costa-Junior,
  • Lorena Lopes Ferreira,
  • Márcia Cristina de Azevedo Prata,
  • Welber Daniel Zanetti Lopes,
  • Caio Monteiro

摘要

Background

In 2022, a tick control product, against Rhipicephalus microplus, containing fluralaner as the active ingredient was initially launched in the Brazilian market, followed by other markets across Latin America. Once a new molecule is introduced for the control of a parasitic organism, it becomes essential to develop methods for assessing the susceptibility of target parasitic populations. In this context, discriminating dose (DD) tests represent a valuable tool.

Methods

This study evaluated the susceptibility profile of 200 R. microplus populations originating from 21 federal units (20 states and a federal district) across all five regions of Brazil, using a larval immersion test (LIT) with two discriminating doses (DD) of 1.55 and 3.16 µg/mL. Populations showing mortality rates above 95% were classified as susceptible. A field trial was also conducted with one population (São José do Rio Pardo [SJRP]), which had a known history of exposure to fluralaner, to compare laboratory and field test outcomes.

Results

The DD at a concentration of 1.55 µg/mL resulted in 100% mortality in 160 populations (80%), whereas the DD at a concentration of 3.16 µg/mL showed more consistent results, with 100% mortality in 182 populations (91%). In the field trial population, SJRP, fluralaner achieved 100% therapeutic efficacy (days +7 to +21) and persistent efficacy (days +28 to +42).

Conclusions

LIT using DDs can provide indicative data on the susceptibility of R. microplus to fluralaner. The discriminating dose at a concentration of 3.16 µg/mL was shown to be the most appropriate for monitoring the susceptibility of R. microplus populations to fluralaner. Laboratory and field data support the classification of the SJRP population as susceptible, demonstrating consistency between the two sets of results. These results can serve as a basis for continuous spatial and temporal monitoring of the susceptibility of R. microplus populations to fluralaner. Continued research, integrating laboratory and field results, is essential to increase the reliability of laboratory-based testing.

Graphical Abstract